1.0Québec Cancer Consortiumhttps://www.cqc-qcc.ca/en/rich600338<blockquote class="wp-embedded-content" data-secret="utUXOv9JcV"><a href="https://www.cqc-qcc.ca/en/members-and-partners/michael-sebag/">Michael Sebag, MD, PhD</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.cqc-qcc.ca/en/members-and-partners/michael-sebag/embed/#?secret=utUXOv9JcV" width="600" height="338" title="“Michael Sebag, MD, PhD” — Québec Cancer Consortium" data-secret="utUXOv9JcV" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.cqc-qcc.ca/wp-includes/js/wp-embed.min.js </script> https://www.cqc-qcc.ca/wp-content/uploads/2021/06/no-photo.jpg500500Dr. Michael Sebag has been working towards improving the lives of patients with Multiple Myeloma (MM) and related disorders since 2006. His focus has been on the preclinical development of novel drugs that target largely unexploited pathways in MM. In collaboration with medicinal chemistry at McGill, his team has developed completely new and interesting molecules […]